Sign In
Buy VTGN
$0.560
-0.0199 (-3.43%)
At Close: Jun 03, 2026
Vistagen Appoints Nick Tressler as Chief Financial Officer
08:30am, Monday, 01'st Dec 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci
Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026
07:45am, Tuesday, 18'th Nov 2025
Vistagen Therapeutics' intranasal pherine drugs target nose-to-brain circuits. This taps into neuropsychiatric, women's health, and oncology indications. Their lead asset is Fasedienol, which is in Ph
Vistagen Therapeutics, Inc. (VTGN) Q2 2026 Earnings Call Transcript
07:01pm, Thursday, 13'th Nov 2025
Vistagen Therapeutics, Inc. ( VTGN ) Q2 2026 Earnings Call November 13, 2025 5:00 PM EST Company Participants Mark McPartland - Senior Vice President of Investor Relations Shawn Singh - President, CEO
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Lags Revenue Estimates
06:55pm, Thursday, 13'th Nov 2025
VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.42 per share a year ago.
Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update
04:30pm, Thursday, 13'th Nov 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci
Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025
08:30am, Monday, 10'th Nov 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci
Vistagen to Participate in Stifel Healthcare Conference 2025
08:30am, Wednesday, 05'th Nov 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci
Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder
08:30am, Monday, 03'rd Nov 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci
Vistagen Appoints Paul Edick to its Board of Directors
08:30am, Wednesday, 29'th Oct 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci
Vistagen to Present at The Menopause Society 2025 Annual Meeting
08:30am, Thursday, 16'th Oct 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci
Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
08:30am, Tuesday, 09'th Sep 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci
Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript
02:13pm, Friday, 08'th Aug 2025
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q1 2026 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Cynthia Lynn Anderson - VP & Chief Financial Officer Joshua S. Prince - Chief
Vistagen (VTGN) Q1 R&D Expense Jumps 54%
11:59pm, Thursday, 07'th Aug 2025
Vistagen (VTGN) Q1 R&D Expense Jumps 54%
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates
08:21pm, Thursday, 07'th Aug 2025
VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.47 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.35 per share a year ago.
